Skip to content

A study to evaluate the efficacy and safety of Shuddhi Vati in comparision with Lactulose in children suffering from chronic constipation

A prospective, comparative, randomized trial to evaluate the clinical efficacy and safety of Shudhhi Vati (ayurvedic drug) in comparison with Lactulose (allopathic drug) in children suffering from chronic constipation

Status
Active, not recruiting
Phases
Phase 3Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/026163
Enrollment
100
Registered
2020-06-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R194- Change in bowel habit

Interventions

Intervention1: Lactulose: Osmotic laxative Liquid medicine: 3.1â??3.7 g in 5 mL of medicine Children: 0.7 to 2 g/kg/day (1 to 3 mL/kg/day) orally in divided doses daily
generally recommended not to exceed the adult maximum of 40 g/day (60 mL/day) for 3 month Control Intervention1: Shudhhi vati: Ayurvedic drug use in children age 5-10 year @ 200 mg tab , 1 tab /day

Sponsors

National Institute Of Medical Sciences Research Jaipur
Lead Sponsor
Patanjali yogpeeth
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1-Healthy children of either gender between 2-14 years of age . 2-Subject in a good clinical condition as judged by the investigator based on 3-3-3-medical history and physical examination Written informed consent obtained from the subjectâ??s parents or legally acceptable representative

Exclusion criteria

Exclusion criteria: 1-Age less than 2 years and more than 14 years. 2-Children with associated conditions like hypothyroidism, celiac disease, Malnutrition, HIV, Malignancies and Acute or Chronic illnesses will be excluded.

Design outcomes

Primary

MeasureTime frame
Average change in passing Frequency & consistency of stool Change in routine activity school going Timepoint: Visit 1: Day 0 â?? Baseline visit Visit 2: Day 7 â?? First follow-up visit Visit 3: One month â?? Second follow-up visit Visit 4: Two month â?? Third follow-up visit Visit 5: Three monthâ?? Fourth follow-up visit Visit 6: Six Month â?? Fifth follow-up visit

Secondary

MeasureTime frame
Passing Blood / Pain/ Distension during trial Find any abnormal investigation parameter during trial Timepoint: 12 Months

Countries

India

Contacts

Public ContactDr Meenaxi Sharma

National Institute Of Medical Sciences & Research Jaipur

vk.hindustani@gmail.com7976406843

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026